Evolus (NASDAQ:EOLS) Stock Price Down 6.5% – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS)’s share price traded down 6.5% during trading on Monday . The stock traded as low as $13.06 and last traded at $13.06. 548,849 shares changed hands during trading, a decline of 41% from the average session volume of 922,538 shares. The stock had previously closed at $13.97.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on EOLS. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st. Finally, Barclays increased their price target on Evolus from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, January 27th.

Evolus Trading Up 4.4 %

The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm’s 50-day simple moving average is $11.98 and its 200 day simple moving average is $13.91. The stock has a market cap of $859.25 million, a P/E ratio of -14.91 and a beta of 1.33.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV acquired a new position in Evolus in the fourth quarter worth approximately $49,000. IFP Advisors Inc lifted its stake in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Evolus in the third quarter worth about $132,000. China Universal Asset Management Co. Ltd. increased its position in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Evolus during the third quarter valued at approximately $191,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.